🇺🇸 FDA
Pipeline program

TAK-041

TAK-041-2001

Phase 2 small_molecule completed

Quick answer

TAK-041 for Stable Schizophrenia is a Phase 2 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).

Program details

Company
NEUROCRINE BIOSCIENCES INC
Indication
Stable Schizophrenia
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials